OneSource Announces Strong Q1FY27 Results
Revenue up 37% YoY and EBITDA up 39% YoY

Performance Highlights

- Revenue of ₹4,490m, up 37% YoY and 5% QoQ, driven by growth in semaglutide commercial launch, new MSA contracts, and customer wins across businesses
- EBITDA of ₹1,233m, up 39% YoY and 34% QoQ, with margins expanding to 27.5%, driven by operating leverage on higher semaglutide revenue
- Adjusted PAT stood at ₹637m with adjusted EPS of ₹5.6

FY28 Guidance Reaffirmation

- $400 million in organic revenue with 40% EBITDA margin

Bangalore, India, July 24, 2026 – OneSource Specialty Pharma Limited *(BSE:544292, NSE: ONESOURCE)* today announced its consolidated financial results for the quarter ended June 30, 2026.

Financial Highlights (In ₹ million)

Particulars	Q1FY27	Q4FY26	QoQ	Q1FY26	YoY
Revenues	4,490	4,282	5%	3,273	37%
EBITDA	1,233	919	34%	885	39%
EBITDA %	27.5%	21.5%	600bps	27.0%	43bps
Adjusted PAT	637	390	63%	371	72%
Adjusted EPS	5.6	3.4	63%	3.2	71%

Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q1FY27: ₹43m, Q4FY26: gain ₹0.3m, Q1FY26: ₹29m) and scheme related intangible amortisation (₹344m in each quarter)

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, "*We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities.*"

Detailed investor communication on the performance of the Company is attached.

About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

Institutional Investors	Corporate Communication
Anurag Bhagania CFO **Tejaswani Fotedar** +91 9004331391 Email: investor-relations@onesourcecdmo.com	**Pallavi Panchmatia:** +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com **Abhilash Mukherjee:** +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com **Harsh Sheth**: +91 9870631557 Email: harsh.sheth@mslgroup.com